摘要
目的评估低剂量强度多西紫杉醇单药每周方案对葸环类药物耐药且体质较差的转移性乳腺癌患者的疗效和毒性。方法30例既往接受过蒽环类药物的MBC患者，多西紫杉醇30mg／m^2，静滴，第1、8、15天，每4周重复，最多接受6个周期化疗。结果30例患者中，完全缓解2例，部分缓解9例，有效率为36．7％（95％可信区间为20．5％～53．9％）。最常见的毒性反应为血液学毒性。全组平均随访15个月，有效者中位疾病进展时间为（1TrP）8．5个月。至随访结束，中位总生存时间（OS）未达到。结论低剂量强度多西紫杉醇单药每周方案对既往接受过蒽环类药物治疗且体质较差的转移性乳腺癌患者较为有效，且耐受性良好。
Objective To evaluate the efficacy and safety of a weekly schedule of low dose-intensity docetaxel monochemotherapy for patients with anthracycline-resistant metastatic breast cancer （MBC） in poor physical status. Methods Thirty MBC patients who were previously exposed to anthracycline treatment received docetaxel alone at a dose of 30 mg/m^2 on D1, D8 and D15, repeated every 4 weeks for a maximum of 6 cycles. Results Of the 30 evaluable patients, 2 （6.7%） achieved a complete response, and 9 （30. 0% ） a partial response, with an overall objective response rate of 36.7% （95% CI： 20.5% -53.9% ）. The most common adverse event was hematologic toxicity. After an average follow-up of 15.0 months, the median time to progression （TIP） was 8.5 months and the median overall survival （OS） had not reached yet at the end of follow-up. Conclusion The weekly low dose-intensity docetaxel monochemotherapy is effective and welltolerated in patients with anthracvcline-resistant metastatic breast cancer in poor physical status.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2008年第4期317-319,共3页
Chinese Journal of Oncology
